Skip to main content

Brain Tumor and Neuro-Oncology Research


Primary GBM


TRIDENT/EF-32

Investigator: Jay Jiguang Zhu, MD, PHD

Lead CRC: Connie Okon

Purpose: To test the efficacy and safety of TTFields with radiation therapy and
temozolomide compared to radiation therapy and temozolomide followed by TTFields and temozolomide in newly diagnosed GBM patients.

Key Inclusion Criteria: GBM Who Grade IV planned tx with RT/TMZ followed by TTTfields; KPS ≥70.

Enrollment Status: Status protocol under development. Expect to open study 4/5 months.

Contact Us: To learn more about this trial, please fill out this short online form »


Recurring GBM


CNS-201

Investigator: Jay Jiguang Zhu, MD, PHD

Lead CRC: Connie Okon

Purpose: To assess the efficacy of Berubicin for Injection in adult subjects with GBM that has recurred or is refractory after standard initial therapy for their disease.

Key Inclusion Criteria: Recurrent or Refractory GBM after standard initial therapy (12 weeks out), measurable tumor of al least 1cm by 1cm,KPS ≥60(Active secondary maliginancies and prior treatment vith Bevacizumab, immunotherapy or anthracyclines are excluded).

Enrollment Status: Protocol under development. Expect to open study 4/5 months

Contact Us: To learn more about this trial, please fill out this short online form »


Brain Metastases


METIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

Investigator: Jay-Jiguang Zhu, MD, PhD

Purpose: To test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain metastases, treated with NovoTTF-100M and supportive treatment compared to supportive treatment alone.

Key Inclusion Criteria: New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study, KPS≥ 70, 1 inoperable brain metastasis or 2– 10 brain lesions per screening MRI.

Enrollment Status: Actively enrolling

Contact Us: To learn more about this trial, please fill out this short online form »


Genomically-Guided Treatment Trial in Brain Metastases

Investigator: Ankush Bhatia, MD

Lead CRC: Kristen Clemons

Purpose: To determine if patients with brain metastases harboring CDK, PI3K, NTRK/ROS1 inhibitors will predict sensitivity to these inhibitors, with targeted therapies.

Key Inclusion Criteria: Histologically confirmed metastatic disease to the brain from any solid tumor; No known leptomeningeal involvement; (concurrent administration of anticancer therapies and chemotherapy within 14 days prior to entering the study are exlcuded)

Contact Us: To learn more about this trial, please fill out this short online form »


CNS


NeMeRe Neoplatic Meningitis Registry

Investigator: Jay Jiguang Zhu, MD, PHD

Purpose: To collect information abut adults wit hNeoplastic Meningitis to better understadn the condition (collaborative study with Penn State)

Key Inclusion Criteria: 18 yrs and older with dx of neoplastic meningitis

Enrollment Status: Actively enrolling

Contact Us: To learn more about this trial, please fill out this short online form »

Clinical Trials

Please fill out the fields to receive information about an ongoing UTHealth Neurosciences clinical trial.
  • This field is for validation purposes and should be left unchanged.